MPW - NYSE

Good morning everyone and welcome to the Q4 2022 Medical Properties Trust's Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions] Please also note, today's event is being recorded. At this time, I would now like to turn the floor over to Charles Lambert, Vice President. Sir, please go ahead.

Thank you. Good morning and welcome to the Medical Properties Trust conference call to discuss our fourth quarter and full year 2022 financial results. With me today are Edward K. Aldag, Jr., Chairman, President and Chief Executive Officer of the company; and Steven Hamner, Executive Vice President and Chief Financial Officer. Our press release was distributed this morning and furnished on Form 8-K with the Securities and Exchange Commission. If you did not receive a copy, it is available on our website at www.medicalpropertiestrust.com in the Investor Relations section. Additionally, we’re hosting a live webcast of today's call, which you can access in that same section. During the course of this call, we will make projections and certain other statements that may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause our financial results and future events to differ materially from those expressed in or underlying such forward-looking statements. We refer you to the company's reports filed with the Securities and Exchange Commission for a discussion of the factors that could cause the company's actual results or future events to differ materially from those expressed in this call. The information being provided today is as of this date only, and except as required by the federal securities laws, the company does not undertake a duty to update any such information. In addition, during the course of the conference call, we will describe certain non-GAAP financial measures, which should be considered in addition to and not in lieu of comparable GAAP financial measures. Please note that in our press release, Medical Properties Trust has reconciled all non-GAAP financial measures to the most directly comparable GAAP measures in accordance with Reg G requirements. You can also refer to our website at medicalpropertiestrust.com for the most directly comparable financial measures and related reconciliations. I will now turn the call over to our Chief Executive Officer, Ed Aldag.

Thank you, Charles and thank you all for listening in today on our fourth quarter earnings call. As one of the largest publicly traded owners of hospitals in the world across 10 different countries on four continents, we find the outlook for our tenants extremely encouraging on all fronts. Recent public comments from US operators confirm the optimism about the industry. Staffing costs are dramatically improved going into 2023, and as is access to qualified patient care staff. And our tenants are implementing innovative means to develop and retain employees. Contract labor costs peaked last March and have come down approximately 33%. Our operators continue to take advantage of advances in technology to increase efficiencies, deliver quality patient care and reduce cost on a per patient basis. My point being that simply because an inflation index is high, doesn't mean that our operators do not have arrows in their quiver to reduce structural costs, transform procedures, et cetera. Hospitals have been for decades required to continually improve process procedures, treatments and optimize charges to maintain equilibrium with a rapidly growing demand for patient treatment. As we move into 2023, the prognosis for generalized margin improvement across the entire industry on an increasing volume is encouraging. Our operators are experiencing low to mid-single-digit comparable revenue increases, depending on the diagnosis, acuity and payer, which, along with improving volumes and expanding reimbursement programs all along the scale are expected to generate an attractive 2023 for MPT's tenants. We've been very busy during all of 2022, maintaining relationships, building new ones and keeping our sights on our abundant opportunities throughout the world. We continue to see tremendous opportunities and are prepared to act on them as soon as the world settles down on the new normal for interest rates. We continue to have a strong pipeline in our current markets like the United States, Europe, and South America but we also continue to explore new markets across the NAFTA and Asian business quarters. Our portfolio continues to produce operating results in line with our original underwriting standards. Like the results posted by the publicly reporting hospital operators, our operators continue to see vast improvements to the labor issues that affected the market this time last year. In December of 2022, we acquired approximately £230 million of additional properties. This addition of six Priory hospitals purchased from a third-party will be added to our master lease with Priory and improve the already strong Priory portfolio. And as you all know, we recently completed the Springstone transaction with Apollo. Springstone will be added to the LifePoint portfolio. This is another good example of our acquiring a holdco spinning out the operating piece out to a third party for profit and retaining the real estate. I'll spend a few minutes reviewing Prospect due to its relevance this quarter. Prospect continues to make progress with their East Coast divestitures in Rhode Island and Connecticut. The transaction in Connecticut with Yale, New Haven Health Systems is still tracking for a midyear close. While the non-MPT facilities in Rhode Island are expected to close in the latter part of 2023. On an extremely encouraging note, intermittent [ph] third-parties have valued Prospect's managed care business at around $1 billion. With our security interest in this managed care business, our share of proceeds from the Yale sale and the excess value in the California properties, we believe we have more than sufficient collateral even without regard to the value of the Pennsylvania properties to more than realize the full return of our investment in prospects, including any deferred rent. In addition to multiple initiatives at their hospitals, Prospect management is focused on an aggressive cost-cutting measure that should enable them to return the Pennsylvania market to profitability in approximately12 to 18 months. The California facilities are currently generating a coverage of 1.2 times on a trailing 12-monthbasis as of the end of the third quarter 2022. That being said, given the elongated timing of the Pennsylvania recovery, we felt it prudent to write off previously recorded straight-line rent and write down the Pennsylvania facilities. Last week, Steward and CommonSpirit announced a definitive agreement for Steward to sell the operations of their Utah facilities to Catholic Health Initiative, a CommonSpirit subsidiary. The purchase price will be used by Steward to pay down debt obligations, including the loan MPT made to Steward last summer and provide Steward with a good amount of liquidity. We announced our agreement to lease our entire Steward Utah hospital portfolio to Catholic Health Initiatives. This will be the second transaction we've done with CommonSpirit, and we are excited to expand this relationship. As you know, CommonSpirit with a credit rating of A is one of the country's largest and most respected not-for-profit health care providers. The announcement made last week regarding Steward's pending sale of its Utah facilities, once again validates the MPT model of underwriting and further validates the value of our entire portfolio. Our track record of underwriting hospital real estate where the demand for the operations, and hence, the value of the underlying real estate and far outlast the operator itself has a 20-year outstanding history. I want to close this part of our earnings call to make a few comments about one in mine and Steve's co-founders, Emmett McLean. Today, we will announce Emmett's retirement from MPT effective on September 1st ,2023. Emmett and Steve and I met in 2003 and have worked closely with each other ever since. It has been a remarkable collaboration of different streams. I want to take this time to publicly thank Emmett for his work and dedication for the past 20 years. Emmett, we know that you and Catherine, your children and those precious grandchildren will cherish your much earned retirement. Congratulations. We will issue a press release and an 8-K later today on Emmett's retirement. Steve?

Thank you, Ed. This morning, we reported normalized FFO of $0.43 and $1.82 per diluted share for the fourth quarter and full year 2022, respectively, in line with our prior expectations. We also introduced our estimate of 2023 calendar net income and normalized FFO, which I will reconcile to the fourth quarter's results momentarily. First, I'll just mention a change we made to our supplemental reporting around our concentration metrics. In prior quarters, we had based operator concentration on an adjusted gross asset basis. That is a non-GAAP basis. Starting this quarter, we are using GAAP numbers. That's because in December 2022, the SEC published updates to its non-GAAP financial measure guidance and basically stated that non-GAAP disclosures in charts, tables, and graphs need to display the related GAAP measure in equal or greater prominence. In order to avoid duplicative disclosures of these charts, tables and graphs, we chose to provide the GAAP-related charts tables and graphs to reduce confusion. However, we did provide our historical non-GAAP concentration metric on our key operators in the footnote to page 11 of our supplemental for comparative purposes to the prior quarters. As described in the press release and Ed's earlier comments, included in the determination of fourth quarter normalized FFO, our adjustments to reserve prospects straight-line rent and the carrying value of our Pennsylvania Prospect's facilities. In conjunction with Prospect's continuing progress in improving its East Coast operations and strategies, we have decided to fully exit our non-California Prospect investments and reallocate that capital to new investments. At the end of this period of transition, we expect that we will have recovered and have available for reinvestment, most or all of our original investment plus any interim deferrals of rent through the following; as we have alluded to in recent months, Prospect owns a valuable managed care business that we believe, based on third-party offers and negotiations and independent valuations is currently worth about $1 billion. More immediately, we continue to expect the pending sale to the Yale New Haven Health System of our Connecticut hospitals to close by late next quarter. We do anticipate also that as hospital operations and financial results improve over the next several quarters, our Pennsylvania hospitals will become increasingly attractive acquisition targets. And proceeds from their future sale will provide additional resources for reinvestment. The accounting adjustment in the fourth quarter to recognize an impairment acknowledges the possibility that such proceeds may be less than our original investment. However, we expect the value of the managed care business will significantly exceed the aggregate amount of the fourth quarter impairment. Any investment unrecovered from cash proceeds from the sale of Connecticut and the non-real estate loan that we originally extended to Prospect in 2019. During this transaction period, and Ed earlier mentioned that it is likely to extend beyond calendar 2023, and -- we are considering providing rent and interest deferral options to Prospect and expect to account for rental income from our non-California Prospect investments, along with any interest from our $115 million non-real-estate loan on a cash basis. And our 2023 guidance estimates take into account the range of our expectations about rent and interest that may not be paid during that period. So, today, we are providing our estimate of calendar 2023 normalized FFO. The following may help investors bridge from our fourth quarter 2022 normalized FFO annualized run rate of about $1.71 to our guidance range of approximately $1.50 to $1.65 for normalized FFO on a calendar basis. Starting with the $1.71. Contractual rent escalations will add about $0.05 a share and the impact of rent and interest income from acquisitions and dispositions and the CommonSpirit Utah transaction, their related cash proceeds and interest expense with respect to transactions in the fourth quarter and through today, is an aggregate pro forma of another $0.03 a share. So, those estimates on their own would yield a guidance estimate of approximately $1.79 of normalized FFO on a Prospect-neutral basis. That is as if Prospect paid all its 2023 rent and interest obligations. Our estimates of potential outcomes regarding Prospect range from a worst-case scenario, in which case we would recognize no rent or interest to our more reasonably expected likely outcome that we recognize most of our California and Connecticut rent, but nothing from the Pennsylvania investment. The per share range of these scenarios would be 2023 normalized FFO of between $1.50 and $1.65 and that is what we reported in this morning's press release. Even at the $1.65 high end of our 2023 guidance, it does not consider incremental FFO that would be created by the recycling of our current investment in our Prospect East Coast investment, assuming succession the restructuring and monetization of Prospect's managed care business. With that, we have time for a few questions, and I'll turn the call back to the operator.

Ladies and gentlemen, at this time, we'll begin the question-and-answer session. [Operator Instructions] Our first question today comes from Austin Wurschmidt from KeyBanc Capital Markets. Please go ahead with your question.

Hey good morning everybody and thanks for the time here. I just want to -- Steve, I want to hit on that -- the guidance and sort of the buildup that you provided. So, it sounds like when all is said and done, that $1.79 captures all of the announced activity that you've announced over the last six-plus months? And would be maybe a reasonable jumping off point once we think about sort of you reinvesting proceeds into any future activity once you've buttoned up the Prospect deal. Is that a fair way to think about it? I'm just trying to understand what sort of the exit rate or run rate is on a go-forward basis once accounting for Prospect?

I think that's generally correct. And again, assumes generally that we will replace the Prospect income with income from new investments, again, assuming the recycling of that capital.

And then I was hoping that you could maybe share with us how to think about sort of the monetization of the managed care? Do you expect to receive proceeds, I guess, from the sale of their managed care business? Or could you end up in some scenario with just a partial investment in that business down the line that maybe takes longer to monetize and ultimately reinvest the proceeds? I mean, is there any time line you can give us on when you expect to received that investment? Or proceeds from that investment?

Yes, I think it's the 12 to 18 months that Ed mentioned earlier. That business, as probably many on this call are aware, is very, very vibrant, very, very attractive right now. And again, we just saw yesterday the Amazon closing of its transaction with a kind of a similar business plan. And it isn't up and running and currently profitable business for Prospect now. And to try to anticipate kind of beyond a 12 to 18-month sale process, which could involve any number of alternatives, and I won't mention them here. But that's our expectation is that -- we hope not to end up with a long-term equity type investment, and we don't think that's the likely outcome. We think it's more likely that there will be a sale or a recapitalization that will recover at least and possibly more than our investment in the East Coast properties.

You're absolutely right. It is our intent as we work through this to push forward sales sooner rather than later, but there are other issues that have to work through.

Understood. And can you just remind us what the total dollar investment is in those 4 Eastern PA hospitals? And then what the contractual annual cash rent that those -- from those buildings?

So, the Pennsylvania hospitals have an aggregate gross investment of about $420 million. Yes, before impairment.

Before impairment. And then we should just describe sort of a high single, low double-digit type yield on that to get to an annual cash rent from those facilities?

Well, that would be right. But just to point out that even in our high end of the range of $1.65. We're not counting on rent from Pennsylvania.

Got it. Understood. Just trying to understand what you'll need to reinvest just sort of recapture I guess that earned rent. That’s all for me. I'll hop back into the queue. Thank you.

Our next question comes from Vikram Malhotra from Mizuho. Please go ahead with your question.

Thanks for taking the questions. Maybe just first on Steward post the Utah transaction, can you maybe just provide two things. One, just any update on your view on underlying cash flow projections as we look at 2023 or other ins and outs? And then just second, the remaining non-Utah, would you give us a sense of like the underlying health of those businesses rent coverage?

Sure, Vikram. The expectations for 2023 continues to be in excess of $350 million, including the Utah facilities. Utah facilities represent approximately $80 million of that. So, somewhere in the $300 million annualized 2023 post the Utah transaction. I think there is a public misnomer thinking that the Utah properties are the most profitable properties in the Steward portfolio. Actually, that is not the case. When the Utah property transaction closes, their overall coverage will actually increase. So, it's an opportunity for them to take proceeds from a mature market from their concern into markets where they had the ability to grow even more. As we've stated before, the Florida properties, in particular, continue to way outperform our original underwriting, and Steward still believes there's tremendous growth there.

Okay, that's helpful. And then just so on this the disclosure based on the new GAAP guidance or SEC guidance, I guess, maybe it seems like a sizable change, and maybe I'm not fully understanding what changed. Would you mind -- I typically won't do this on the call, but would you mind just giving us an example, like takes the Steward Florida or Circle Health, -- just explain to us like what changed in the disclosure -- and it would be helpful if you can maybe in an update, give us just -- I know it's a lot more pages, but give us the pro forma versus what changed? And I guess, again, I'm not understanding what changed because I didn't see like other REITs having to make this change in their supplements?

So, the biggest change is, I'll just address that generally, and we can absolutely supplement our supplement with our prior guidance. But the big changes were, again, just changes, for example, to deduct depreciation, accumulative depreciation, that affects obviously the relative and the overall denominator of the calculation. And then in our prior pro forma examples, we would pro forma for example, binding contracts for transactions that had not yet closed. So, just by the way, I'll give you a very brief example here. If you have the supplement in front of you, page11, and you look at the Steward Health care, the aggregate of all of the Steward Health care markets shown in the GAAP basis statement is 24.2%. Had we presented this on the old method, it would have been, as the footnote says, it would have been 19.8%. And again, instead of going through line by line, the details of that, we'll get, as I say, a supplement to the supplement.

Okay. That would be helpful. If you can bridge the two with all the gap like you said, depreciation because I felt both were net, but maybe I'm just reading it incorrectly and then any pro forma adjustments. Just to clear -- just to make it like crystal clear, in terms of what you did. Just last question. Can you remind us just in an effort to shore up more cash flow and hopefully reduce leverage going forward? Can you remind us sort of any update on, say, the Australian assets or other assets that you may be monetizing? What the underlying appetite is for hospital real estate today?

Well, we don't have anything to report on Australia. But other than to address your question, we continue to see strong appetite across the geographies, and that's indicated by unsolicited occasional but fairly frequent inquiries about our assets across Western Europe. And although we've never acknowledged the Australian sale process, we don't deny it, but we have nothing to report on that at this time.

Okay. Thank you.

Our next question comes from Steven Valiquette from Barclays. Please go ahead with your question.

Great. Thanks. Good morning. Thanks for taking the question. And also, I appreciate the extra color on Prospect Medical, maybe just to provide some additional updated color around their underlying operations within the Pennsylvania hospitals. Just remind us what the key variables are to improve the profitability of the operations. And I recall there was some conjecture to potentially repurpose some of those PA assets into alternative use, I believe, on the behavioral side, but that may have hit some road blocks. I'm just curious if you can just give us an update on these collective dynamics and just path to improvement for these Pennsylvania hospitals just based on what you know right now. Thanks.

Sure Steve. As we've all talked about previously, that particular area was hit harder with COVID than a lot of other areas in the United States, and that's not just from a patient standpoint, but probably worse from a staffing standpoint, the rules that we all used to have to go by, if you tested positive COVID if you even tested for COVID, most hospitals don't even test for COVID anymore. So most of those issues have been resolved. But you're right, when they originally bought these facilities, they had a plan, which we knew about and in light of repurposing a number of the facilities. The problem is you've got facilities there that are very close to each other that are providing the same services and we think they had a very good plan for repositioning what services were provided in each individual facility. What I guess none of us took into account was the political fallout that would cause various politicians saying, well, I'm not -- don't take my hospital the way those types of things. That's been much harder than any of us realized. I think that as Prospect has gone through this, the politicians have been much easier to work with as of late. So, we have -- we do have hope that they can do what their original plan was and repurposing some of those facilities. I don't want to make a plan based on the last month and -- two months and a half. But their operating statistics all look dramatically better than they did this time last year. And so they're clearly making some progress, but two and a half months don't make a real plan at this point.

Okay, all right. Appreciate that color. Thanks.

Our next question comes from Michael Carroll from RBC Capital Markets. Please go ahead with your question.

Thanks. I wanted to stay on Prospect. And I guess, Steve, you made some comments that provided prospects with some potential over rent options. I mean what do those options include? And had they made a decision on what they wanted to do with those options?

No, I think just to be clear, we're considering that, and we expect that we will provide some fairly significant rent options, rent deferral options. Again, going back to Ed's opening comments about Prospect, it's going to be at least a 12 to 18-month process. And that's the reason, for example, we gave the worst-case scenario. As if during 2023, we collect nothing from Prospect. That's what gets you to the $1.50. So that truly is a worst-case scenario. We do expect to provide Prospect some alternatives to manage its cash flow across the quarters, but we have not finalized that yet. And just because we are presenting a worst-case scenario of collecting no rent, that's not necessarily to imply that that's what we intend to offer Prospect.

What -- under what scenario would you defer all your rent? I mean if they ask for it, would you necessarily provide that to them?

Well, we're a long way from that. There are lots of parties involved in the Prospect strategies and negotiations. And we have simply said that along with other parties, we are willing to consider contributing to Prospect's 2023 cash needs and primarily by virtue of potential rent concessions, rent deferrals.

Did Prospect pay their full rent in January and February?

No.

Okay. Did they pay any rent in January and February?

That we haven't disclosed, but no, they did not pay their full rent.

Okay. And then under what scenario, I guess, do you that this will be completed. I know in the press release, you highlighted that this will take 12 to 18 months, but then you also indicated that you would expect to get some recoveries in the second half of the year. I mean, what's the give and takes with that potential outcome?

Yes. Well, it's the Yale sales, the Connecticut sale, the improvement of the overall operations in the facilities and an ultimate conclusion of a restructuring for them.

Okay. And then last question for me. What transaction taken so long? I know in the middle of 2022, you kind of expected something will get done in the fourth quarter. So why is it being pushed out further into 2023 -- it sounds like probably 2024?

Well, we did expect -- we had good reason to expect in the fourth quarter actually going into the first quarter and into the early weeks of January. We I say we Prospect was negotiating with a potential financial partner that would have begun the monetization process of the managed care business that would have provided immediate liquidity for operations. And those negotiations went very deep, and it was only in the middle of January that it became apparent that, that particular party was not going to continue to move forward. And that's what -- that's the big change that caused us to make these accounting decisions.

Okay, great. Thank you.

Our next question comes from Michael Mueller from JPMorgan. Please go ahead with your question.

Take you off mute there. So, first of all, I guess after the Connecticut assets are sold, are you anticipating a rent cut on Pennsylvania and the California assets on a go-forward basis? And is any of that baked into that $0.15 cash recovery?

No, the difference -- the primary difference between the $1.50 worst-case scenario, which, again, not to belabor it, but assumes no rent at all from any Prospect properties. The difference between that $1.50 and the $1.65 is primarily collection of the Connecticut rent and collection of the California rent and interest.

Got it. But on a go-forward basis, so you're assuming -- what are you assuming on a go-forward basis, not necessarily calendar 2023, but for the Pennsylvania assets. are you anticipating some sort of rent there? Or just that operating--

I think at any point along the range of $1.50 to $1.65, there is no Pennsylvania rent assumed there. Ideally, we'd like to see Pennsylvania improved -- and as I mentioned earlier, become an attractive -- it is an acquisition target. And you all may recall, this time last year, there was an offer, a non-binding offer from an investment-grade rated not-for-profit. And it is still an attractive facility for operators. So our preference would be for that to happen and Prospect defined a buyer and we actually sell the real estate and recover at least the impaired value of the real estate.

Mike, those hospitals aren't going away as can be seen in the political fight about any potential closures of any particular parts of hospitals. People want those hospitals. The politicians want those hospitals all to stay open. We just believe this is already proven to us to be taking longer than we had anticipated. And we just don't know any more at this point to how quickly Pennsylvania can be resolved. But it's not a zero.

Got it. Okay. And then, I guess, on the managed care side, the $1 billion appraised value there. I guess --how should we think about how much of that you're entitled to from, I guess, your -- what you have structured into the leases. It sounds like you think that if it's $1 billion as a base case, should we be thinking that you're entitled to, at least based on what you're telling us, the $170 million that you've kind of written down on the PA assets. So, that's kind of the minimum threshold of what you think you can kind of -- you're entitled to out of the $1 billion valuation.

Yes, I think a different way to look at it, Mike, would be that we think we're entitled to enough of it to get all of our money back, including obviously what we're going to get out of Connecticut and what we think the value of California is.

Okay. Thank you.

Our next question comes from Tayo Okusanya from Credit Suisse. Please go ahead with your question.

Yes, good morning everyone. So a couple from me. Again, still on prospects. So again, you guys have moved to cash basis. I'm curious if from an auditor's perspective, Prospect has any issues around being a going concern. If it does, how do you guys kind of think about the potential bankruptcies there on a plan B for getting a new operator for those assets?

So, we certainly haven't had anybody to raise the concern of a going concern at this particular point. But we believe we are in the same place whether this is a bankruptcy or work together restructuring standpoint. Obviously, if it's a bankruptcy, it may take a little bit longer, but we still believe we're in a good position to recover all of our investments, including the deferred rent.

Okay, that's helpful. And then number two, moving on to priority. Could you talk a little bit about just the economics of that transaction, the cap rates you did the deal at and also the seller financing what interest rates that was done at?

Yes, this is the one we just announced this morning, the additional six properties. These are six properties that were not owned by Priory when we bought the original transaction. These are owned by a third-party who put them up for sell middle of late last year, last summer. And we've been working with them. They -- we believe they are some of the very best assets for Priory. And they will be added to the master lease with Priory go under the same terms that are there. We believe it will help even improve what's already a strong coverage there and a strong collateral base.

But in regards to actual cap rates on it and as well as the funding cost on the seller financing and assumed debt. Is that something you can provide?

No, as you know, Tayo, we normally don't give specific cap rates other than this is attractive and accretive and even on a cash basis with the seller financing is cash flow accretive. And again, is included in the guidance that we gave. I mentioned earlier the I think, roughly $0.03 net accretion to the transactions that we announced this morning.

Okay, great. Then can we move over to kind of current leverage and just taking a look at the balance sheet and some of the moving items there that kind of contributed towards higher leverage with the line of credit kind of going up a decent amount. It seems like, again, your accounts receivables increased there's this kind of additional mortgage loans increase of about $60 million. Just kind of talk about kind of some of the items that may have contributed to the higher use of the line and higher net debt.

Sure. The calculation we showed this morning at 6.4 times -- and just to be clear, we footnoted that based on the range of potential outcome with Prospect. But starting with the baseline 6.4 is up from last quarter 5.8. That's due primarily, as I mentioned, to the effect of the range of Prospect assumptions. Secondly, as you mentioned, our acquisition of the Priory assets in the fourth quarter funded with seller financing and the impact of currency movements. The $60 million you mentioned was a European investment we made in the fourth quarter. And I think that's about it, right, yes.

And then the AR receivables being up $50 million, and anything going on there with would kind of slower.

Yes, Prospect is a big piece of unpaid billed rent.

Got you. Okay. And then from an accounting perspective, just bear with me. I appreciate the explanation about the change to net investments that you discussed earlier on, Steve. The only challenge is when we have that change, when we don't see gross investments, we can't really see any additional investments that were made -- could you just talk about, again, since you guys did the $250 million of investments to Steward and Prospect if there were any additional investments to those two operators since that time?

No, other than routing order business, for example, the development funding that goes on with -- of course, there's no development funding and prospect. There's the [indiscernible] Norwood construction projects with Steward. But that that's the increased investment.

Got you. Okay. That's helpful. And then just one final comment from me. I think, again, just having the EBITDA rent coverages that you used to provide in the past, I think investors do find that useful. It would be great if you could see a return of those metrics in the next supplemental in 1Q 2023. Thank you very much.

Thanks Tayo.

Our next question comes from John Pawlowski from Green Street Advisors. Please go ahead with your question.

Thanks for the time. Maybe a follow-up to Tayo's question. Did you provide any operators at all financial support in the fourth quarter through the rent deferrals, loans, equity stakes? Or do you expect to have to in the coming quarters outside of Prospect?

Was that final part? Do we expect to--

Yes, do you expect to outside of Prospect?

Aside from Prospect. No, we don't.

Okay. Maybe going back to the prospects restructuring, Steve, I think you alluded to -- you expect to collect most of the California rents. So -- can you just take a step back, and I know you put some scenarios in there. I'm less concerned about worst-case scenarios that are embedded in guidance. I'm just trying to understand the actual reality in terms of how much cash is going to come in the door this year. So, the total Prospect relationship what percent of your annual cash payments that are owed by Prospect do you actually expect to collect this year, use a range, if you like? And just -- we just need some quantification.

Well, I think we've given the range. We don't expect the worst case. It's possible that the $1.65, which, as you point out, is basically collection of the California rent and six months of Connecticut, assuming we sell Connecticut at the end of the six months.

And those are cash not freight [ph].

Okay. But do you -- so is I right to interpret that there's going to be a shortfall in the California rent collection as well?

That's quite possible, yes.

Okay. Are they paying rent currently under the California for hospitals?

No. For -- as I mentioned a little earlier, very little of January, February rent has been paid.

Okay. Last one for me. I assume the repayment of the upsized mortgage loans didn't occur in the fourth quarter. Can you give us a sense for when you expect that mortgage loan to be repaid in the California properties?

Along with the recovery from primarily the sale of the managed care business although there are other restructuring options with respect to that particular facility. That facility, obviously, as you point out, is mortgage now. We are considering a number of options that could include acquisition of that facility for the mortgage balance, but there's nothing definitive or binding with respect to that possible strategy.

Okay. Thank you.

Our next question comes from Andrew Rosivach from Wolfe Research. Please go ahead with your question.

Hey good morning guys. How are you?

Hey Andrew, fine. Thank you.

I was thinking maybe something that might help if you -- would you be able to translate kind of your FFO into an AFFO guidance? Because I'm guessing some of the puts and takes related to Prospect are probably related to cash basis versus straight line?

I got lost in that question. I'm sorry.

Sorry, Steve. So -- so you have an FFO of $1.50 to $1.65. And I think a lot of us are trying to back into dividend coverage. And I'm guessing that if we took a step from 2022 to 2023, the difference in AFFO is less than the difference in FFO.

Yes. So, if you take that worst-case scenario again at $1.50, and you make necessary adjustments for AFFO, we're at about $1.29.

Got it. Okay. Thank you very much. And then my second one is really nerdy, and I know -- some of these numbers are estimated, but your schedule for tenant disclosures, you used to have EBITDAR and EBITDARM you now have EBITDA. I'm just curious why you went to one column.

Yes. And Andrew, you may remember that we stopped doing EBITDAR a long time ago because it was confusing because a lot of that are assumptions that everyone has to make, including us about what the M part of the EBITDARM is. For example, if you look at that page, which is page 14 in the supplement. A number of those operators EBITDARM and the EBITDAR is the same thing. So, what we did a long time ago when we were trying to show EBITDAR, we used an arbitrary number for us from -- that we got from what the management fee may be -- many times, those were much higher than actual numbers. Another example, we have a couple of operators who prefer not to be named in this report, although it doesn't take a genius to figure out which ones those are. But the -- we own a very small part of their overall portfolio. So, it's not easy to try to go from EBITDA to EBITDAR based on when you own a very small part of the overall portfolio. So, what you see here on EBITDARM is what we've been reporting for a long time. And obviously, you can go back and look at what the various trends are. And you'll see that the overall trend for most of our operators is up in the right direction. So it's just that EBITDAR wasn't a scientific number, as we talked about in great detail, I believe, this time last year, it was -- we had a lot of subjectivity to it.

You're typically taking -- you're making, I'm guessing an assumption of an expense as a percentage of revenues or...

That's correct. Yes.

Or is EBITDARM is an actual number that you're getting? That’s correct.

Terrific. Thanks a lot guys.

And our next question is a follow-up from Vikram Malhotra from Mizuho. Please go ahead with your follow-up.

Thanks. Just two quick follow-ups. First, can you just clarify the Utah sale to CommonSpirit. My quick calculation, I think the new rent, is it about 10% lower on a cash basis. Can you clarify, was there a rent change with CommonSpirit?

Yes. Yes, there was a rent change. On a cash basis, they're paying -- you can do the arithmetic. They're paying 7.8% on the roughly $1.22 billion of investment. That's a reduction from what Steward paid in 2022 by a little more than $6 million. Some of that $6 million will be recovered through reallocation of that rent back to other Steward facilities. And again, all that's built in to the guidance numbers we gave.

Okay, that's helpful. And then can you just maybe give us a little bit more color on the guidance components on two things. Just what's the what's the straight line rent baked into the guide on either end of the range, if you can? And also what the G&A range is, if it's possible?

I think we'll probably have to get back to you on that. I don't think anybody around this table has an immediate answer, especially the straight line, the G&A is a recent run rate.

Okay. Thank you.

And our next question is also a follow-up from John Pawlowski from Green Street Advisors. Please go ahead with your follow-up.

Thanks for taking the second question. Steve or Ed, what level of leverage on a debt-to-EBITDA basis on your metrics do you expect to be running at this time next year? I think Ed's opening remarks, we're pretty bullish on acquisition pipelines, but there's -- there's a lot of moving pieces in terms of potential dispositions. So, this time next year, what level of leverage can shareholders expect you to be running at?

Let me make the point about the acquisitions that I was trying to make in the prepared remarks there. We have a great pipeline -- but until we get a new norm for where interest rates are around the world, there's not going to be a whole lot of acquisitions from us. As we have said throughout the year, we will continue to support our existing customers and other very strategic moves like we did with the Priory transaction we announced today. But other than that, I'm just making the point that -- the pipeline is strong. We're continuing to work out those relationships.

Yes. And what goes unsaid, probably don't need to be said with that, we certainly don't expect to be leveraging up to take advantage of marginally accretive transactions.

We expect leverage to remain essentially unchanged? Or do you expect to do?

Well, no, we expect it to remain in that five to six times that we were working on and making great progress on until the latter part of last year. So, that remains our strategy is to maintain that level of long-term leverage -- and to do that, along with making accretive acquisitions, we need to see, first, as Ed has mentioned now, some certainty in the cost of debt. And we need to see some rationality on the part of sellers for recognizing that the cost of capital is driving down the otherwise value of their assets. And until all that happens, and we can access affordable equity-type capital, then we won't be making significant acquisitions, certainly not if that means driving up leverage.

Okay. Thank you.

And ladies and gentlemen, with that, we will end today's question-and-answer session. I'd like to turn the floor back over to Ed Aldag for any closing remarks.

Jamie, thank you very much. And as always, we appreciate your listening in and your interest. -- have any follow-up questions, please don't hesitate to give us a call. Thank you very much.